Chem. J. Chinese Universities ›› 2025, Vol. 46 ›› Issue (5): 20240524.doi: 10.7503/cjcu20240524

• Articles:Analytical Chemistry • Previous Articles     Next Articles

Development of a Glycosyl-imprinted Sensor and Rapid Detection of PD-L1 Positive Exosomes in Breast Cancer

LUO Kui1, LIN Jiaxi2, LI Jianping1,2()   

  1. 1.College of Environmental Science and Engineering
    2.College of Chemistry and Bioengineering,Guilin University of Technology,Guilin 541004,China
  • Received:2024-11-29 Online:2025-05-10 Published:2025-02-14
  • Contact: LI Jianping E-mail:likianping@263.net
  • Supported by:
    the National Natural Science Foundation of China(22264010)

Abstract:

A glycosylated electrochemical sensor for rapid identification and detection of breast cancer PD-L1 positive exosomes was developed. First, glycosyl-imprinted polymers(GIP) were prepared by electropolymerization using glyco-Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Gal overexpressed by breast cancer positive exosome glycoprotein PD-L1 as template molecules and 3-aminophenylboronic acid as functional monomers. After elution and removal of template molecules, an imprinted membrane that can specifically recognize PD-L1 positive exosomes was obtained. Potassium ferricyanide was used as a probe to measure the DPV current value of the GIP electrode. Exosomes were cleaved with RIPA to deduct free protein interference, and the change in current value(ΔI) was recorded. ΔI decreased with the increase of the concentration of readsorbed PD-L1-positive exosomes, and was linearly positively related to the logarithmic value of the concentration. The detection range was 2.36×102—1.18×107 particles/mL, and the detection limit was 93 particles/mL. The method has been used to detect breast cancer PD-L1-positive exosomes in clinical samples, and its spiked recoveries were 93.82%—105.32%. The sensor could be used to screen breast cancer in clinical samples by the difference in glycosylation degree.

Key words: Exosome, Glycosyl-imprinting, Electrochemical sensor, PD-L1, Breast cancer

CLC Number: 

TrendMD: